[Flunarizine in drug-resistant epilepsies of childhood and adolescence].
Therapeutic effects of flunarizine have been studied on 26 patients, aged from 9 months to 17 years, suffering for epilepsies resistant to common anticonvulsant treatment, despite proper plasmatic levels of drugs. All the cases were monitored with monthly clinical and EEG controls, neuropsychological evaluations and monitoring antiepileptic drugs plasmatic levels. At first, a study was performed on an intra-patient basis: after a basal observation during two months, an open clinical trial was started, using for three months flunarizine 5 mg a day in patients weighing over 10 kg, and 5 mg every two days in children weighing less than 10 kg. Later on, a simple blind clinical trial has been performed on 16 patients, using flunarizine or placebo for three months. The results, obtained in resistant epilepsy of children and adolescent, showed that flunarizine induced in 47.6% of cases a significant reduction of critical (stroke) frequency and intensity, together with normalization of sleeping-waking rhythm, and amelioration of attention performances (vigilance, reactivity, environmental participation). The only side-effect, noticed in 23.8% of cases, was a light diurnal sleepiness, spontaneously regressing after a few days of treatment.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002936:Cinnarizine / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D004828:Epilepsies, Partial / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy* / Q000209:etiology; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy; D005444:Flunarizine; D006801:Humans; D007223:Infant; D013577:Syndrome
D002936:Cinnarizine; D005444:Flunarizine
La flunarizina nelle epilessie farmaco-resistenti dell'infanzia e dell'adolescenza.